GENTIAN DIAGNOSTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.8 NOK | +2.51% |
|
+8.51% | -1.69% |
| Apr. 29 | Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors | CI |
| Apr. 29 | Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 3.4 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.69% | 55.83M | - | ||
| -0.60% | 12.95B | B+ | ||
| -9.59% | 7.84B | B- | ||
| +1.82% | 5.5B | B | ||
| +0.02% | 4.61B | C | ||
| +7.53% | 4.61B | C | ||
| -47.68% | 3.4B | D+ | ||
| +6.42% | 2.66B | - | - | |
| -14.59% | 2.08B | B- | ||
| +2.93% | 1.79B | C |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GENT Stock
- Ratings Gentian Diagnostics
